DOP2017000121A - Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson - Google Patents

Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson

Info

Publication number
DOP2017000121A
DOP2017000121A DO2017000121A DO2017000121A DOP2017000121A DO P2017000121 A DOP2017000121 A DO P2017000121A DO 2017000121 A DO2017000121 A DO 2017000121A DO 2017000121 A DO2017000121 A DO 2017000121A DO P2017000121 A DOP2017000121 A DO P2017000121A
Authority
DO
Dominican Republic
Prior art keywords
parkinson
antagonist
disease
low dose
adhd treatment
Prior art date
Application number
DO2017000121A
Other languages
English (en)
Inventor
Areberg Johan
Breysse Nathalie
Chandrasena Gamini
Frydelund Larsen Lone
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of DOP2017000121A publication Critical patent/DOP2017000121A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a dosis específicas de un antagonista de A2A para utilizarlo como un medicamento y, en particular, que sean útiles para el tratamiento de la enfermedad de Parkinson y del trastorno por déficit de atención con hiperactividad.
DO2017000121A 2014-12-03 2017-05-16 Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson DOP2017000121A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03

Publications (1)

Publication Number Publication Date
DOP2017000121A true DOP2017000121A (es) 2017-07-15

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000121A DOP2017000121A (es) 2014-12-03 2017-05-16 Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson

Country Status (25)

Country Link
US (2) US20160158211A1 (es)
EP (1) EP3226863A1 (es)
JP (1) JP2017536400A (es)
KR (1) KR20170090430A (es)
CN (1) CN106999480A (es)
AU (1) AU2015357197A1 (es)
BR (1) BR112017011777A2 (es)
CA (1) CA2966582A1 (es)
CL (1) CL2017001407A1 (es)
CO (1) CO2017004785A2 (es)
CR (1) CR20170221A (es)
DO (1) DOP2017000121A (es)
EA (1) EA201790973A1 (es)
EC (1) ECSP17030050A (es)
IL (1) IL252355A0 (es)
MA (1) MA41090A (es)
MX (1) MX2017007027A (es)
NI (1) NI201700066A (es)
PE (1) PE20170926A1 (es)
PH (1) PH12017500923A1 (es)
SG (1) SG11201704370XA (es)
SV (1) SV2017005441A (es)
TN (1) TN2017000174A1 (es)
TW (1) TW201632186A (es)
WO (1) WO2016087429A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349550B (en) * 2003-12-26 2011-10-01 A thiazole derivative and adenosine a2a receptor antagonist containing the same
NZ590793A (en) * 2008-07-23 2012-07-27 Kyowa Hakko Kirin Co Ltd Therapeutic agent for migraine
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
CR20170221A (es) 2017-10-05
TW201632186A (zh) 2016-09-16
AU2015357197A1 (en) 2017-05-25
MX2017007027A (es) 2017-08-24
SV2017005441A (es) 2017-08-25
KR20170090430A (ko) 2017-08-07
IL252355A0 (en) 2017-07-31
TN2017000174A1 (en) 2018-10-19
US20160158211A1 (en) 2016-06-09
JP2017536400A (ja) 2017-12-07
CN106999480A (zh) 2017-08-01
WO2016087429A1 (en) 2016-06-09
NI201700066A (es) 2018-01-04
PH12017500923A1 (en) 2017-11-20
BR112017011777A2 (pt) 2018-02-20
ECSP17030050A (es) 2017-08-31
CL2017001407A1 (es) 2018-01-05
EP3226863A1 (en) 2017-10-11
SG11201704370XA (en) 2017-06-29
US20180125835A1 (en) 2018-05-10
CO2017004785A2 (es) 2017-08-31
MA41090A (fr) 2017-10-10
PE20170926A1 (es) 2017-07-13
CA2966582A1 (en) 2016-06-09
EA201790973A1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2017004983A (es) Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP17030050A (es) Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
BR112017016333A2 (pt) compostos anticâncer
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
CL2015001481A1 (es) Uso de extracto bacopa monnieri
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
PT3154597T (pt) Métodos de preparação para uma nova geração de produtos biológicos de klh seguros utilizados para o tratamento de cancro, para o desenvolvimento de de vacinas conjugadas terapêuticas e como agentes competitivos
DOP2015000290A (es) Benzoxazoles sustituidos